Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ligand Pharmaceuticals Inc. (LGND:NASDAQ), powered by AI.
Ligand Pharmaceuticals Inc. is currently trading at $255.25. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Ligand Pharmaceuticals Inc. on Alpha Lenz.
View Ligand Pharmaceuticals Inc.'s valuation metrics on Alpha Lenz.
“Ligand Pharmaceuticals Inc.'s ROE is 13.5%. Explore profitability and growth together.”
Ask for details →Ligand Pharmaceuticals Inc. is a biopharmaceutical company that specializes in developing technologies and assets that aid in the discovery process and production of vital therapeutic drugs. The company's primary function is to support pharmaceutical innovation through its proprietary technology platforms, including Captisol, a chemically modified cyclodextrin used to improve the solubility and stability of drugs. Ligand operates in a diverse range of therapeutic areas, placing significant impact on industries related to oncology, inflammation, and infectious diseases, enhancing the effectiveness and delivery of treatments. Noteworthy for its business model, Ligand does not focus on manufacturing its own complete lines of medicines. Instead, it partners with a wide array of pharmaceutical companies, licensing its technologies to advance drug development, thus generating a stream of royalty and milestone revenues. Headquartered in San Diego, California, Ligand Pharmaceuticals plays a critical role in the drug development pipeline, enabling and expediting the creation of revolutionary medical solutions that save lives while maintaining a flexible and diversified portfolio of healthcare investments.
“Ligand Pharmaceuticals Inc.'s ROE is 13.5%. Explore profitability and growth together.”
Ask for details →Ligand Pharmaceuticals Inc. (ticker: LGND) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 68 employees.
The current price is $255.25 with a P/E ratio of -x and P/B of -x.
ROE is 13.47% and operating margin is 17.61%. Annual revenue is $268M.